Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 3/20 | 0.64 |
| ▸ | BRAF | P15056 | 11/20 | 0.49 |
| ▸ | EGFR | P00533 | 9/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2316154 | 0.88 | KIT (0.49) | KITBRAFEGFRHTTMEN1 | |
| SCHEMBL18298084 | 0.87 | KIT (0.71) | KITBRAFEGFRHTTMEN1 | |
| SCHEMBL19073340 | 0.86 | KIT (0.48) | KITBRAFEGFRHTTMEN1 | |
| SCHEMBL2316261 | 0.84 | MAPT (0.53) | KITHTTMEN1NPC1MAPT | |
| SCHEMBL23111995 | 0.84 | KIT (0.67) | KITBRAFEGFRHTTMEN1 | |
| SCHEMBL21611712 | 0.83 | KIT (0.65) | KITBRAFHTTMEN1NPC1 | |
| SCHEMBL29561783 | 0.83 | KIT (0.65) | KITBRAFHTTMEN1NPC1 | |
| SCHEMBL19073344 | 0.81 | BRAF (0.47) | KITBRAFEGFRHTT | |
| SCHEMBL5498213 | 0.80 | KIT (0.61) | KITBRAFHTTMEN1NPC1 | |
| SCHEMBL2317440 | 0.79 | KIT (0.43) | KITBRAFEGFRHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988389-B2 | Processes for making ponatinib and intermediates thereof | APICORE US LLC (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988389-B2 | Processes for making ponatinib and intermediates thereof | APICORE US LLC (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180044345-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2018-02-15 | — | — | US | disclosed |
| US-20180044345-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2018-02-15 | — | — | US | disclosed |
| US-20160362411-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2016-12-15 | — | — | US | disclosed |
| US-20160362411-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2016-12-15 | — | — | US | disclosed |
| WO-2016201203-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE US LLC (US) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016201203-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE US LLC (US) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044345-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | KIT 436/4885BRAF 12/4885EGFR 26/4885 |
| US-20160362411-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | KIT 436/4885BRAF 12/4885EGFR 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.